Rucaparib Synthesis via Catalytic Hydrogenation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The conventional synthesis of Rucaparib, a PARP inhibitor, involves complex and time-consuming steps with the generation of toxic HCN gas, reducing yield and making large-scale production challenging.
Innovation Solution
A method involving the conversion of a compound into another using methylamine, followed by hydrogenation with a catalyst like Pd/C to produce the tricyclic compound, bypassing intermediate isolation and reducing agent-induced toxicity, thereby simplifying the process and enhancing yield.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional synthesis using NaBH3CN as reducing agent is used, then imine compounds can be reduced, but toxic HCN gas is generated
Solution Approach 1:
The patent replaces the harmful chemical reducing agent NaBH3CN with a physical reduction method using hydrogen gas and catalyst. This converts a harmful chemical process into a cleaner physical-chemical process that produces water instead of toxic HCN gas, while maintaining the reduction capability needed for synthesizing Rucaparib.
Solution Approach 2:
The patent substitutes the chemical mechanism (NaBH3CN reduction) with a catalytic hydrogenation mechanism using H2 gas and metal catalysts (Pd, Pt, or Ni). This replacement eliminates the generation of toxic cyanide byproducts while achieving the same reduction of imine compounds to amine products.
2Manufacturing precision
If multiple synthetic steps and purification steps are used, then Rucaparib can be obtained, but total yield is reduced and time is increased
Solution Approach 1:
The patent combines the synthesis step and purification step into a single integrated process. By using catalytic hydrogenation followed by direct filtration to remove the catalyst, the method eliminates intermediate isolation and multiple purification operations, thereby increasing overall yield and reducing production time while maintaining product purity.
Solution Approach 2:
The patent extracts and removes only the essential purification step (filtration to remove catalyst) while eliminating redundant synthesis and purification operations. This streamlined approach retains the necessary purity control while dramatically improving productivity by reducing the number of steps from multiple synthetic and purification operations to just two main steps.
3Manufacturing precision
If multiple synthetic steps and purification steps are used, then Rucaparib can be obtained, but production time is increased
Solution Approach 1:
The patent merges multiple sequential operations (synthesis, intermediate purification, isolation, and final purification) into a single continuous process where the reaction mixture is directly filtered to remove catalyst and obtain pure product. This integration eliminates time losses associated with intermediate handling and multiple purification cycles.
Solution Approach 2:
The patent maintains continuous productive action by proceeding directly from the hydrogenation reaction to final product isolation through filtration, without interrupting the process for intermediate purification or isolation steps. This continuous approach maximizes productivity while ensuring product purity through the single critical filtration step.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method simplifies the synthesis, increases yield to over 70%, and avoids the generation of toxic HCN gas, making it suitable for mass production and reducing production costs.
Implementation Method 1
hydrogenating the compound of formula (III) under hydrogen to produce the tricyclic compound of formula (I) in the presence of a hydrogenation catalyst
Implementation Method 2
hydrogenating the compound of formula (III) under hydrogen to produce the tricyclic compound of formula (I) in the presence of a hydrogenation catalyst, in which R1 is H or a C1-3 alkyl group and R2 is H, a halogen element or a C1-3 alkyl group
Data Source
AI summary
A method of preparing a tricyclic compound of formula (I), comprising the step of converting a compound of formula (II) into a compound of formula (III); and hydrogenating the compound of formula (III) in the presence of hydrogenation catalyst and hydrogen to form the tricyclic compound of formula (I); wherein R1 is H or a C1-3 alkyl group; and R2 is H, a halogen element or a C1-3 alkyl group.